Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.
Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N.
Kirito K, et al. Among authors: akashi k.
Int J Hematol. 2018 Jan;107(1):92-97. doi: 10.1007/s12185-017-2332-z. Epub 2017 Oct 6.
Int J Hematol. 2018.
PMID: 28986762